Review our pipeline for a detailed overview of our key initiatives and their status in the development and testing process.

Development of Quicksol™, involves a patented process to improve solubility of traditionally insoluble molecules such as drugs in the macrocyclic lactone class.  With Quicksol™, we are able to form macrocyclic cyclodextrin inclusion complexes that when combined with a surfactant and dissolved in water, can form aqueous solutions.   The process includes the use of FDA approved non-ionic solvents to increase solubility and bioavailability of the molecule, opening possibilities for parenteral administration of drugs that have poor oral absorption

Challenges with livestock infections and administration of medication to cure animal infectious disease has caused significant reductions in yield across a variety of animal species, leading to pressure on agriculture economics, livestock management, and the overall production of food for the globally growing human population. We have applied our patented solubility technology to the drug Ivermectin and have developed the only form in the world that uses excipients that are currently approved by the US Food and Drug Administration, making it a leading candidate for broad husbandry animal treatments.

Cold chain is a temperature-controlled supply chain that prescribes necessary conditions during the transport, storage, and handling of vaccines and drugs administered. With Quicksome™ technology we are working to enable vaccine distribution outside of cold chain, which will potentially support the use of less vaccine per dose, cost reduction, increase vaccine output, and be key for global disease eradication.

In oncology our work is currently focussed on applying our our Quicksol™ technology to reformulate existing molecules with anti-cancer effects as potential oncology treatments. Published literature has shown very interesting in vitro results for the potential effect of the macrocyclic lactone class on a wide variety of tumor types. Applying our technology to this class, and to other insoluble molecules, allows the investigation of these potential anti-cancer therapies as new options for oncology treatment. 

Production of a stable, quick onset,  oral dissolve formulation to provide potential benefits of precise dosing, reduced variability, and dose sparing.

The purpose of the Company’s PANA process is to produce stable nano-particulate adjuvant with the intention of overcoming certain limitations of traditional aluminum-based adjuvants. The potential to use less vaccine per dose with a dose sparing adjuvant could lead to a number of potential benefits including: cost reduction, increased vaccine output, facilitation of mucosal and herd immunity, long-term stability in aqueous media, applications across hundreds of vaccines, and a key to global disease eradication.

Although there has been significant innovation in recent years in relation to diabetes, insulin remains a cornerstone of treatment and that there is an unmet need in the insulin space, resulting from challenges such as costs, the use of needles, hypoglycaemia, and fear of injection. The company is currently exploring the application of QuicksomeTM technology to the needle-less administration of insulin through formulation experiments, to optimize the potential delivery of rapid-acting human insulin in a sublingual format.

Application of patented Quicksol™ technology to the macrocyclic class of drugs to assess anti-infective properties across a wide range of diseases.